GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
May 24 2022 - 9:00AM
IND-Enabling Studies Underway in the United States for
MVA-VLP-MUC1 Vaccine Candidate
via NewMediaWire -- GeoVax Labs,
Inc. (Nasdaq: GOVX), a biotechnology company developing
human immunotherapies and vaccines against infectious diseases and
cancer, today announced that the Chinese Patent Office has issued a
Notice of Allowance for GeoVax’s patent application titled
“Compositions and Methods for Generating an Immune Response to a
Tumor Associated Antigen.”
The claims to be granted by the patent generally
cover GeoVax’s vector platform for expressing tumor associated
antigens in virus-like particles (VLPs) from a Modified Vaccinia
Ankara (MVA) viral vector and encompass GeoVax’s Mucin 1 (MUC1)
tumor-associated antigen immunotherapy candidate. The Company uses
its GV-MVA-VLP™ vaccine platform to express abnormal, aberrantly
glycosylated forms of the cell surface-associated MUC1 protein that
is associated with a wide range of cancers, including breast,
colon, ovarian, prostate, pancreatic, and lung.
GeoVax’s initial results with its MVA-VLP-MUC1
immunotherapy candidates have been encouraging and the Company
recently began an IND-enabling animal study with Dr. Pinku
Mukherjee at the University of North Carolina at Charlotte to
define the optimal course and schedule of vaccination to define a
protocol that can be evaluated in a Phase 1 clinical trial. GeoVax
believes that its MVA vector platform is well-suited for
development of therapeutic cancer vaccines based on the expression
of tumor-associated antigens such as MUC1 and Cyclin B1.
David Dodd, GeoVax President and CEO, commented,
“This patent allowance complements the previously issued U.S.
Patent No. 11278607, demonstrating the global importance of this
technology, and adding to our growing portfolio of wholly owned,
co-owned, and in-licensed intellectual property, which now stands
at over 70 granted or pending patent applications spread over 20
patent families. GeoVax is committed to advancing meaningful cancer
immunotherapies towards improving the lives of patients
worldwide.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer using novel proprietary
platforms. GeoVax’s product pipeline includes two ongoing Phase 2
clinical trials of GEO-CM04S1 for COVID-19 as a universal booster
vaccine to mRNA vaccines authorized by the U.S. Food and Drug
Administration (FDA) and as a primary vaccine for use in
immunocompromised patients. In addition to GEO-CM04S1 for COVID-19,
GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The
Company is also conducting a Phase 1/2 clinical trial of Gedeptin®
for treatment of head and neck cancer. Gedeptin® has been granted
orphan drug status by the FDA. Additional research and development
programs include preventive vaccines against Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and
malaria, as well as immunotherapies for multiple solid tumors. The
Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our
website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our registration statement on Form S-1 and the
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2023 to Sep 2024